A Study of LY900014 in Participants With Type 1 Diabetes

Completed · Phase 3

Conditions studied: Type 1 Diabetes Mellitus

In brief

The main purpose of this study is to evaluate the efficacy of the study drug LY900014 compared to insulin lispro, both in combination with insulin glargine or insulin degludec, in adults with type 1 diabetes (T1D).

Key facts

Study ID

NCT03214367

Run by

Eli Lilly and Company

People needed

1392

Starts

2017-07-17

Expected to finish

2019-08-22

Last updated by the study team

2020-05-01

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Have T1D for at least 1 year prior to screening and continuously using insulin for at least 1 year.
• HbA1c of ≥7.0 and ≤9.5%.
• Use insulin lispro, insulin aspart, or insulin glulisine as prandial insulin.
• Use insulin glargine, insulin detemir, insulin degludec, or neutral protamine Hagedorn (NPH) insulin as basal insulin.

You may not qualify if…

• Have used other antihyperglycemic medications or therapies (inhaled, oral or injectable) within 90-days of screening.
• Have had more than 1 severe hypoglycemic episode within 6 months of screening.
• Have had more than 1 hospitalization related to hyperglycemia or diabetic ketoacidosis within 6 months of screening.
• Have clinically significant gastrointestinal disease.

Where it is running

• John Muir Physician Network Clinical Research Center — Concord, California, United States
• AMCR Institute INC — Escondido, California, United States
• Valley Endocrine, Fresno — Fresno, California, United States
• Marin Endocrine Associates — Greenbrae, California, United States
• Diabetes and Endocrine Associates — La Mesa, California, United States
• University Clinical Investigators, Inc. — Tustin, California, United States
• Coastal Metabolic Research Centre — Ventura, California, United States
• Barbara Davis Center for Childhood Diabetes — Aurora, Colorado, United States
• The Center For Diabetes & Endocrine Care — Fort Lauderdale, Florida, United States
• East Coast Institute For Research — Jacksonville, Florida, United States
• Sun Coast Clinical Research, Inc — New Port Richey, Florida, United States
• Metabolic Research Institute Inc. — West Palm Beach, Florida, United States
• Atlanta Diabetes Associates — Atlanta, Georgia, United States
• East Coast Institute For Research — Macon, Georgia, United States
• Endocrine Research Solutions, Inc. — Roswell, Georgia, United States
• East West Medical Institute — Honolulu, Hawaii, United States
• Northwest Clinical Trials — Boise, Idaho, United States
• Rocky Mountain Diabetes and Osteoporosis Center — Idaho Falls, Idaho, United States
• Prairie Education and Research Cooperative — Springfield, Illinois, United States
• Iderc, P.L.C. — West Des Moines, Iowa, United States
• University of Kansas Medical Center — Kansas City, Kansas, United States
• Cotton O'Neil Diabetes and Endocrinology Center — Topeka, Kansas, United States
• Kentucky Diabetes Endocrinology Center — Lexington, Kentucky, United States
• MassResearch — Waltham, Massachusetts, United States
• Internal Medicine Center LLC — Mobile, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.